spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

3P Biopharmaceuticals appoints José Luis Bartolomé as Operational Excellence Director

3P Biopharmaceuticals

Professional with extensive experience in biotechnology companies


[Noáin, Spain, September 30, 2020]3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, appoints a new member to the management team with the incorporation of José Luis Bartolomé as Operational Excellence and Continuous Improvement Director.

José Luis Bartolomé has a solid profile in equipment and operations management and joins 3P Biopharmaceuticals with the aim of improving the company's internal processes.

José Luis comes to 3P with more than 30 years of experience in the biotechnology sector. He has a degree in biology from Santiago de Compostela University and throughout his extensive experience has worked in different biotechnology companies.

His professional career began in 1986 at Cooper Zeltia, and later he worked in the production department of companies such as Wellcome-Biofarma, Glaxo, Genentech and Lonza, in all of which he was a Production Manager. Before joining the 3P team, he was General Manager at Laboratorios Ovejero.

Therefore, his professional career has been developed in GMP environments, and he is an expert in the implementation of technology transfers, as well as working in facilities and processes subject to continuous customer audits or by different regulatory authorities (FDA, AEMPS, etc.)

“I appreciate the confidence 3P has shown me by giving me the opportunity to work with such a highly qualified team. I hope to contribute my experience in leading biotechnology companies to achieve excellence through continuous improvement”, explained Bartolomé.

Dámaso Molero, CEO at 3P Biopharmaceuticals said:"it is a pleasure to welcome José Luis to 3P and to incorporate such an experienced profile into our management team. I am sure that his arrival will give a boost to 3P in many aspects”.

“With my previous experience I hope to help analyze situations and processes that can be modified for our clients greater satisfaction and confidence, as well as strengthen 3P to optimize employee development and their professional growth”, added Bartolomé.

Therefore, with this new addition to the management team,3P Biopharmaceuticals continues its growth plan and consolidates a competitive position as one of the leading CDMOs in Europe.

About 3P Biopharmaceuticals
 
3P Biopharmaceuticals is a leading CDMO specialized in process development and GMP manufacturing of biologics and cell therapy products. 3P offers solutions at all stages of biologics development, from the initial process and analytics development to preclinical and clinical phases and commercial production. Its extensive experience, flexibility, and adaptation, as well as its innovative technology and qualified team, have made 3P an example for the international market. For further information: http://www.3pbio.com/ 

3P Biopharmaceuticals contact:
Isabel García
Communications & Marketing at 3P Biopharmaceuticals
Phone: + 34 948 346 480
email: igarcia@3pbio.com
phone +34 948 34 64 80
email info@3pbio.com
web www.3pbio.com
email Polígono Mocholí, C/ Mocholí 2, 31110 Noáin, Navarra, Spain
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders

July 12, 2020 - The Data Demonstrating Benefits of Pharmacokinetic-Guided Prophylaxis Therapy in Hemophilia and von Willebrand Disease are Among 13 Presentations from Takeda’s Hematology Portfolio and Pipeline
More info >>


White Papers

Clinical Trial Labelling – More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement